Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Acute myeloid leukemia cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	BMI1 (1) AMPK (2) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (1) Apoptosis (50) Arenavirus (1) Autophagy (3) Bacterial (2) Bcl-2 Family (3) Bcr-Abl (3) Btk (1) c-Fms (1) c-Kit (2) c-Myc (3) Caspase (3) CD3 (1) CDK (5) Ceramidase (1) ClpP (1) Cuproptosis (1) Dihydroorotate Dehydrogenase (1) DNA Methyltransferase (2) DNA/RNA Synthesis (2) E1/E2/E3 Enzyme (3) Endogenous Metabolite (2) Epigenetic Reader Domain (11) Eukaryotic Initiation Factor (eIF) (1) FGFR (1) FLT3 (27) GSK-3 (1) HDAC (12) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (1) Histone Demethylase (7) Histone Methyltransferase (1) HIV (1) Interleukin Related (1) Isocitrate Dehydrogenase (IDH) (4) KLF (1) LPL Receptor (1) MARK (2) MDM-2/p53 (5) MNK (1) Monoamine Oxidase (1) mTOR (1) NF-κB (1) P-glycoprotein (1) p38 MAPK (1) PDGFR (1) PI3K (3) Pim (3) PROTACs (7) Reactive Oxygen Species (2) RET (1) Salt-inducible Kinase (SIK) (2) SF3B1 (1) SphK (1) STAT (3) Topoisomerase (1) Trk Receptor (1) VEGFR (1)
By Research Areas:	Cancer (117) Infection (3) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (1)

By Targets:

BMI1 (1)

AMPK (2)

Anaplastic lymphoma kinase (ALK) (1)

Antibiotic (1)

Apoptosis (50)

Arenavirus (1)

Autophagy (3)

Bacterial (2)

Bcl-2 Family (3)

Bcr-Abl (3)

Btk (1)

c-Fms (1)

c-Kit (2)

c-Myc (3)

Caspase (3)

CD3 (1)

CDK (5)

Ceramidase (1)

ClpP (1)

Cuproptosis (1)

Dihydroorotate Dehydrogenase (1)

DNA Methyltransferase (2)

DNA/RNA Synthesis (2)

E1/E2/E3 Enzyme (3)

Endogenous Metabolite (2)

Epigenetic Reader Domain (11)

Eukaryotic Initiation Factor (eIF) (1)

FGFR (1)

FLT3 (27)

GSK-3 (1)

HDAC (12)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Acetyltransferase (1)

Histone Demethylase (7)

Histone Methyltransferase (1)

HIV (1)

Interleukin Related (1)

Isocitrate Dehydrogenase (IDH) (4)

KLF (1)

LPL Receptor (1)

MARK (2)

MDM-2/p53 (5)

MNK (1)

Monoamine Oxidase (1)

mTOR (1)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (1)

PDGFR (1)

PI3K (3)

Pim (3)

PROTACs (7)

Reactive Oxygen Species (2)

RET (1)

Salt-inducible Kinase (SIK) (2)

SF3B1 (1)

SphK (1)

STAT (3)

Topoisomerase (1)

Trk Receptor (1)

VEGFR (1)

By Research Areas:

Cancer (117)

Infection (3)

Inflammation/Immunology (6)

Metabolic Disease (2)

Neurological Disease (1)

121

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99014

Cusatuzumab 1 Publications Verification ARGX-110	Apoptosis	Inflammation/Immunology Cancer
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .

HY-129592

p-Tolylmaleimide	Apoptosis	Cancer
p-Tolylmaleimide (compound 9) is a naphthalimide derivative that has cytotoxic effects on cancer cells. p-Tolylmaleimide can arrest the cell cycle of human acute myeloid leukemia cells K562 in the sub-G0/G1 phase and induce apoptosis .

HY-144779

HDAC10-IN-1	HDAC Autophagy	Cancer
HDAC10-IN-1 (compound 13b) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 58 nM. HDAC10-IN-1 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-144782A

HDAC10-IN-2 hydrochloride	HDAC Autophagy	Cancer
HDAC10-IN-2 hydrochloride (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 hydrochloride modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-169067

10-Methoxy-canthin-6-one Mtx-C	p38 MAPK	Cancer
0-Methoxy-canthin-6-one (Mtx-C) is a DNA damage inducer. 0-Methoxy-canthin-6-one promotes cell cycle arrest at the G2/M phase by intercalating into DNA, thereby inducing myeloid differentiation of acute myeloid leukemia (AML) cells and leukemic stem cells (LSCs). The myeloid differentiation in AML and LSC cells is characterized by increased expression of myeloperoxidase, CD15, CD11b, and CD14, as well as activation of p38 MAPK. 0-Methoxy-canthin-6-one can be used in leukemia research .

HY-162906

FLT3/HDAC-IN-2	HDAC FLT3	Cancer
FLT3/HDAC-IN-2 is (compound 25h) a FLT3/HDAC dual inhibitor. FLT3/HDAC-IN-2 has antiproliferative activity against MOLM-13 cells. FLT3/HDAC-IN-2 can be used in acute myeloid leukemia research .

HY-144782

HDAC10-IN-2	HDAC Autophagy	Cancer
HDAC10-IN-2 (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-162936

SILA-123	FLT3 Apoptosis	Cancer
SILA-123 is a FLT3 inhibitor (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM). SILA-123 inhibits FLT3 phosphorylation and downstream signaling pathways, leading to apoptosis by arresting cell cycle progression at the G0/G1 phase. SILA-123 can be used in the study of acute myeloid leukemia .

HY-144675

LSD1-IN-13	Histone Demethylase	Cancer
LSD1-IN-13 (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-144675A

LSD1-IN-13 hydrochloride	Histone Demethylase	Cancer
LSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-128888B

(S,R)-GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
(S,R)-GSK321 is a potent, selective mutant IDH1 inhibitor with IC₅₀ values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. (S,R)-GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. (S,R)-GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .

HY-115906

K783-0308	FLT3 MNK Apoptosis	Cancer
K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC₅₀ values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC₅₀=10.5 µM) and MV-4-11 (IC₅₀=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase .

HY-164542

TQ05310	Isocitrate Dehydrogenase (IDH)	Cancer
TQ05310 is an orally available inhibitor of IDH2 mutants, targeting both IDH2-R140Q (IC₅₀=136.9 nM) and IDH2-R172K (IC₅₀=37.9 nM) mutants. TQ05310 inhibits the production of 2-hydroxyglutarate (2-HG) and induces differentiation of cells expressing IDH2-R140Q and IDH2-R172K by inhibiting the enzymatic activity of mutant IDH2. TQ05310 can be used for the study of acute myeloid leukemia .

HY-142696

CDK6/PIM1-IN-1	CDK Pim Apoptosis	Cancer
CDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC₅₀ values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC₅₀=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity .

HY-136175

Revumenib 5+ Cited Publications SNDX-5613	Epigenetic Reader Domain	Cancer
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

HY-139877

OXS007417	Others	Cancer
OXS007417 induces differentiation of acute myeloid leukemia cells (EC₅₀ = 48 nM) in vitro and shows antitumor effects in vivo.

HY-146749

FLT3/TrKA-IN-1	FLT3 Trk Receptor Apoptosis	Cancer
FLT3/TrKA-IN-1 is a potent FLT3/TrKA dual kinase inhibitor with the IC₅₀s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively. FLT3/TrKA-IN-1 induces cell cycle arrest at the G0/G1 phase as well as apoptosis and shows antiproliferative activity in vitro. FLT3/TrKA-IN-1 has the potential for the research of Acute myeloid leukemia (AML) .

HY-148422

Rohinitib	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML .

HY-110071

APcK110	c-Kit	Cancer
APcK110 is a potent Kit inhibitor that can be used for the research of acute myeloid leukemia (AML). APcK110 induces AML cell apoptosis .

HY-B0722

Histamine dihydrochloride 5+ Cited Publications	Endogenous Metabolite Reactive Oxygen Species	Metabolic Disease Cancer
Histamine dihydrochloride is a reactive oxygen species (ROS) inhibitor. Histamine dihydrochloride can suppress ROS production and work together with IL-2 to activate T cells and NK cells, leading to immune activation in the tumor microenvironment, which consequently kills acute myeloid leukemia (AML) cells. Histamine dihydrochloride can cause a reduction in vaginal tetrazo reduction, increased epithelial growth, and heightened keratinization in mouse models of ovariectomy. Histamine dihydrochloride can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-16271

Kevetrin hydrochloride 1 Publications Verification 4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride	MDM-2/p53 Apoptosis	Cancer
Kevetrin hydrochloride is a potent activator of p53, induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells .

HY-115406A

CPTH6 hydrobromide	Apoptosis	Cancer
CPTH6 hydrobromide is a thiazole derivative which activates apoptotic program and increases autophagic features in human acute myeloid leukemia cell lines. CPTH6 can be used for cancer research .

HY-B0722R

Histamine dihydrochloride (Standard)	Endogenous Metabolite Reactive Oxygen Species	Metabolic Disease Cancer
Histamine (dihydrochloride) (Standard) is the analytical standard of Histamine (dihydrochloride). This product is intended for research and analytical applications. Histamine dihydrochloride is a reactive oxygen species (ROS) inhibitor. Histamine dihydrochloride can suppress ROS production and work together with IL-2 to activate T cells and NK cells, leading to immune activation in the tumor microenvironment, which consequently kills acute myeloid leukemia (AML) cells. Histamine dihydrochloride can cause a reduction in vaginal tetrazo reduction, increased epithelial growth, and heightened keratinization in mouse models of ovariectomy. Histamine dihydrochloride can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma .

HY-161149

CM-1758	HDAC	Cancer
CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells .

HY-13297

PYZD-4409 1 Publications Verification	E1/E2/E3 Enzyme	Cancer
PYZD-4409 is a specific inhibitor of the ubiquitin-activating enzyme UBA1 with an IC₅₀ of 20 μM (cell-free enzymatic assay). PYZD-4409 induces cell death in malignant cells and preferentially inhibits the clonogenic growth of primary acute myeloid leukemia cells .

HY-18626

NK 314	Topoisomerase	Cancer
NK 314 is an inhibitor for topoisomerase IIα, which generates the break of DNA double-strand. NK 314 arrests the cell cycle at G2 phase in human acute myeloid leukemia cells, inhibits the proliferation of CEM with IC₉₀ of 55 nM .

HY-164515

ONC213	Apoptosis	Cancer
ONC213 is an αKGDH inhibitor that suppresses mitochondrial respiration and elevates α-ketoglutarate levels by inhibiting αKGDH activity, leading to apoptosis (Apoptosis) in AML cells. ONC213 can be used in acute myeloid leukemia research .

HY-112041

Unesbulin 3 Publications Verification PTC596	BMI1 Apoptosis	Cancer
Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity .

HY-125151

BP-1-108	STAT Apoptosis	Cancer
BP-1-108 is a selective inhibitor of STAT5 (K_i=8.3 μM) with anticancer activity. BP-1-108 induces apoptosis of leukemia cells by inhibiting the phosphorylation of STAT5. BP-1-108 can be used in the study of acute myeloid leukemia and prostate cancer .

HY-101266

Milademetan 2 Publications Verification DS-3032	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces *G1 cell* cycle arrest, senescence and apoptosis** .

HY-101266B

Milademetan tosylate hydrate 2 Publications Verification DS-3032b; DS-3032 tosylate hydrate	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces *G1 cell* cycle arrest, senescence and apoptosis** .

HY-13680

Meisoindigo Dian III; N-Methylisoindigotin; Natura-α	Apoptosis	Cancer
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .

HY-139535

Luxeptinib CG-806	FLT3 Btk Apoptosis	Cancer
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells .

HY-158341

IOX5	HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
IOX5 is a selective prolyl hydroxylases (PHD) inhibitor. IOX5 stabilizes HIF-1α in AML cells, induces apoptosis, and upregulates BNIP3 expression. IOX5 compromises development and progression of acute myeloid leukemia .

HY-N0071

Crotonoside Isoguanosine	FLT3 HDAC	Cancer
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-163541

SMS121	Others	Cancer
SMS121 is a CD36 inhibitor. By targeting the lipid uptake protein CD36, SMS121 blocks the pathway of fatty acid entry into AML cells to reduce the uptake of fatty acids by AML cells, thereby reducing the activity of these cells. SMS121 can be used to study acute myeloid leukemia (AML) .

HY-124629

DB2313 1 Publications Verification	Apoptosis	Cancer
DB2313 is a potent transcription factor PU.1 inhibitor with an apoptosis of 14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects .

HY-N2492

(E)-Methyl 4-coumarate Methyl trans-p-coumarate	Bacterial Apoptosis	Infection Cancer
(E)-Methyl 4-coumarate (Methyl 4-hydroxycinnamate), found in several plants, such as Allium cepa or Morinda citrifolia L. leaves. (E)-Methyl 4-coumarate cooperates with Carnosic Acid in inducing apoptosis and killing acute myeloid leukemia cells, but not normal peripheral blood mononuclear cells. Antioxidant and antimicrobial activity.

HY-129079

TFMB-(R)-2-HG 1 Publications Verification	Others	Cancer
TFMB-(R)-2-HG, a cell membrane-permeable version of (R)-2-HG, is a carcinogenic factor in Acute myeloid leukemia (AML). TFMB-(R)-2-HG impairs SCF ER-Hoxb8 cells differentiation in response to estrogen withdrawal .

HY-121725

MM-206	STAT	Cancer
MM-206, a STAT3 activity inhibitor, potently inhibits the STAT3 SH2 domain-phosphopeptide interaction with IC₅₀ of 1.2 μM. MM-206 demonstrates dose-dependent induction of apoptosis in acute myeloid leukemia (AML) cell lines .

HY-149981

P-gp inhibitor 13	P-glycoprotein	Cancer
P-gp inhibitor 13 is a P-gp inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .

HY-103275

Adaphostin NSC 680410	Bcr-Abl Apoptosis	Cancer
Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent p210 ^bcr/abl inhibitor (IC₅₀=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC₅₀ ranging from 17 to 216 nM). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells .

HY-155556

ZG36	ClpP	Cancer
ZG36 is a human Caseinolytic protease P (ClpP) agonist. ZG36 non-selectively degrades respiratory chain complexes and reduces mitochondrial DNA, ultimately leading to mitochondrial dysfunction and leukemic cell death. ZG36 also inhibits the development of acute myeloid leukemia in a xenograft mouse model .

HY-162386

UM4118	Cuproptosis	Cancer
UM4118 is a copper ionophore that can initiate a mitochondrial-based noncanonical form of cell death known as cuproptosis. UM4118 exhibits high sensitivity in SF3B1-mutated and adverse risk acute myeloid leukemia (AML), and can be used for AML research .

HY-155153

CDK9-IN-24	Apoptosis CDK	Others
CDK9-IN-24 (compound 21a) is a highly selective CDK9 inhibitor with significant inhibitory effect on tumor growth. CDK9-IN-24 effectively blocks cell proliferation and induces apoptosis by downregulating Mcl-1 and c-Myc, and can be used in acute myeloid leukemia research .

HY-121917

Ro 31-7837	c-Myc Apoptosis	Inflammation/Immunology
APTO-253 (LOR-253) hydrochloride is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 hydrochloride mediates anticancer activity via induction of Kruppel-like factor 4 (KLF4) tumor suppressor. APTO-253 hydrochloride exhibits antiarthritic activity.

HY-122240

AAE871	FLT3	Cancer
AAE871 is a potent type I FLT3 inhibitor with an IC₅₀ value of 0.034 µM. AE871 has the potential for the research of acute myeloid leukemia (AML) .

HY-19541A

I-CBP112 hydrochloride	Epigenetic Reader Domain	Cancer
I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (K_ds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin .

HY-163160

BET-IN-23	Apoptosis Epigenetic Reader Domain	Cancer
Bet-in-23 (Compound 23) is a BD2-selective BET inhibitor with an IC₅₀ of 2.9 nM. BET-IN-23 has anticancer activity and can significantly inhibit the proliferation of acute myeloid leukemia (AML) cell lines by inducing G0/G1 arrest and apoptosis in vitro .

HY-162250

MS8847	PROTACs Histone Methyltransferase	Cancer
MS8847 is a highly potent EZH2 PROTAC degrader that recruits the E3 ligase von Hippel-Lindau (VHL). MS8847 potently degrades EZH2 in a ubiquitin-proteasome system-dependent manner. MS8847 effectively inhibits the growth of acute myeloid leukemia (AML) and triple-negative breast cancer (TNBC) cells .

Cat. No.	Product Name	Target	Research Area

HY-P3508A

PNC-27 acetate	MDM-2/p53	Cancer
PNC-27 acetate, a chimeric p53-penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. PNC-27 acetate is an anticancer peptide. PNC-27 acetate can be used in acute myeloid leukemia research .

HY-P3508

PNC-27	MDM-2/p53	Cancer
PNC-27, a chimeric p53-penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. PNC-27 is an anticancer peptide. PNC-27 can be used in acute myeloid leukemia research .

Cat. No.	Product Name	Target	Research Area

HY-P99014

Cusatuzumab 1 Publications Verification ARGX-110	Apoptosis	Inflammation/Immunology Cancer
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks